IMMX Stock Discussion

Immix Biopharma, Inc. Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. It is developing IMX-110 that is in Phase Ib/IIa clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. The company has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase Ib clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc. was incorporated in 2012 and is based in Los Angeles, California.

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Autoimmune Disease Inflammation Colorectal Cancer Sarcoma Ulcerative Colitis Abdominal Pain Crohn's Disease Soft Tissue Sarcoma Beigene